Psilocybin and Nicotine Addiction: What an 80% Quit Rate Actually Means

In 2014, a team at Johns Hopkins led by Matthew Johnson published a result that most addiction researchers assumed was a typo: 80% of participants had quit smoking at the 6-month mark. Not 80% reduction in cigarettes smoked. Not 80% who made a serious attempt. Complete abstinence, biochemically verified with urine cotinine and carbon monoxide breath testing, at six months — in a population that had been smoking for an average of 31 years and had tried quitting a median of six times before. For comparison: varenicline (Chantix), the most effective pharmaceutical option available, achieves roughly 33–35% abstinence at six months in the best-designed trials. Nicotine replacement therapy averages 15–25%. Cold turkey is approximately 5%. Psilocybin-assisted therapy produced a quit rate more than double the best available medicine. The 12-month follow-up published in 2017 showed 67% still abstinent — still triple varenicline at the same timepoint.

These numbers are not just clinically significant. They are paradigm-disrupting. They suggest that addiction researchers have been wrong about what nicotine addiction fundamentally is — and that psilocybin was accidentally revealing the answer.

Why Nicotine Is Deceptively Hard to Quit

Ask most people why nicotine addiction is difficult to overcome and they will describe physical withdrawal: the irritability, the cravings, the restlessness. They are not wrong that these symptoms exist. But they are describing the wrong problem. The physical component of nicotine dependence is among the mildest of any addictive substance. Withdrawal peaks within 72 hours and is largely resolved by two weeks. The physiological hook of nicotine is weaker than caffeine in terms of its withdrawal severity.

The reason nicotine addiction has a 95% failure rate for cold turkey attempts — and why most people who do quit will try seven or more times before succeeding — is not the receptor. It is the architecture around the receptor. Smoking becomes embedded in identity, in automatic behavioral sequencing, in emotional regulation, in social context, in self-narrative. "I am a smoker" is not a description of a habit. It is a load-bearing element of the self-concept. It organizes dozens of small daily decisions, rituals, and coping strategies that have been rehearsed thousands of times. Varenicline can block nicotinic acetylcholine receptors. It cannot touch the narrative architecture. It cannot tell the brain that the chapter has ended.

The Default Mode Network: Addiction's Hidden Architecture

The default mode network (DMN) is a constellation of midline cortical structures — medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), angular gyrus, and retrosplenial cortex — that activate during rest and self-referential processing. When you are not attending to an external task, the DMN comes online. It runs autobiographical memory, future simulation, self-modeling, and the continuous background process of constructing a coherent "I" across time.

For most of the 20th century, the DMN was invisible to addiction researchers because it was not the target of any known drug. Dopamine was the target. The mesolimbic system — VTA to nucleus accumbens — was the addiction circuit. And dopamine is genuinely important: nicotine releases dopamine in the reward pathway, which is why it feels good and why cessation produces dysphoria. But the dopamine story explains why you become addicted. It does not explain why you cannot stop once you want to.

The DMN explains the latter. When a habitual smoker's DMN activates — which happens dozens of times per day, during every idle moment, every transition between tasks, every stressful conversation — it retrieves the behavioral program it has executed most consistently in those states: reaching for a cigarette. The DMN does not evaluate this retrieval. It is not a deliberative process. It is more like a default posture: when nothing else is happening, this is what we do. The smoker does not decide to want a cigarette. The DMN delivers the wanting pre-formed.

Robin Carhart-Harris and Karl Friston proposed in 2010 that the DMN functions as the brain's ego-maintenance system — continuously enforcing a stable, self-consistent model of who you are and how you behave. Addiction, in this framework, is not primarily a dopamine disorder. It is a DMN rigidity disorder. The addicted brain's self-model has the addiction built into it, and the DMN actively defends that model against update.

How Psilocybin Hits the DMN

Psilocybin is a prodrug. After oral ingestion, it is rapidly dephosphorylated by alkaline phosphatase in the gut and liver to psilocin, which crosses the blood-brain barrier and acts primarily as a partial agonist at 5-HT2A serotonin receptors. These receptors are densely expressed in the cortical layer V pyramidal neurons of the mPFC and PCC — the anchor nodes of the DMN.

The consequence of 5-HT2A activation in these regions is not simply excitation or inhibition. It is a dramatic disruption of the oscillatory coherence that defines the DMN's resting-state activity. Neuroimaging studies by Robin Carhart-Harris at Imperial College London showed that under psilocybin, the DMN's internal connectivity essentially collapses — the synchronized oscillations that make the network function as a unified unit break down. BOLD signal in the mPFC and PCC drops sharply. The DMN's "grip" on brain-wide activity loosens. Other networks that are normally suppressed when the DMN is active begin communicating with each other in unusual patterns — a state of what researchers call "neural entropy," where the brain explores a wider range of functional configurations than it normally accesses.

This is what psilocybin experiences phenomenologically feel like: the dissolution of the fixed sense of self. The loosening of the narrative "I." The perception that who you are is not as solid or inevitable as you thought. In the context of addiction, this is not a side effect. It is the mechanism.

The Serotonin System and Why 5-HT2A Specifically

Serotonin modulates an enormous range of functions — mood, appetite, sleep, social behavior, anxiety — but not all serotonin receptors are equally relevant to the therapeutic effects of psilocybin. The 5-HT2A subtype, particularly when expressed in cortical pyramidal neurons, is responsible for the dramatic psychedelic effect and appears to be the primary driver of therapeutic outcomes.

5-HT2A activation in layer V pyramidal neurons of the mPFC triggers a burst of glutamate release that cascades into increased AMPA receptor activity and downstream BDNF (brain-derived neurotrophic factor) signaling through TrkB receptors. This is the molecular initiating event for psilocybin's neuroplastic effects — a serotonin receptor triggering a growth factor cascade that ultimately drives new synaptic connections.

Critically, nicotine also has serotonergic effects — it desensitizes 5-HT3 receptors and indirectly modulates 5-HT release — which means the serotonin system has been altered by years of nicotine exposure in the smoker population. Psilocybin's 5-HT2A engagement may be particularly powerful in this population because it recruits a receptor subtype that nicotine itself largely ignores, opening a neurochemical pathway to change that has not been worn smooth by the addiction.

Neuroplasticity: The Structural Evidence

The psychological disruption of the DMN is temporary — psilocybin's half-life is approximately 2–3 hours for psilocin, and acute neuroimaging changes resolve within 6 hours. Yet the therapeutic effects of a single session persist for months or years. This durability requires a structural explanation, and that explanation arrived in 2021.

Alex Kwan's laboratory at Yale (Shao et al., 2021) used in vivo two-photon microscopy to image dendritic spine dynamics in mouse frontal cortex before, during, and after psilocybin administration. The findings were striking: a single psilocybin dose produced a 10% increase in dendritic spine density in prefrontal cortical neurons within 24 hours. More importantly, the new spines persisted for at least a month — the full duration of the observation window. The researchers also noted that psilocybin selectively enhanced spine growth on the apical dendrites of layer V pyramidal neurons, the same cells that express 5-HT2A receptors and that the DMN depends on for its self-referential computations.

Dendritic spines are the physical structures that encode synaptic connections. More spines mean more potential pathways for neural information to travel. In the context of addiction recovery, increased dendritic spine density in the prefrontal cortex means increased capacity for the prefrontal cortex to exert top-down control over subcortical impulse systems — including the dopaminergic reward circuits that drive craving. The structural change creates the biological substrate for the behavioral change.

David Olson at UC Davis coined the term "psychoplastogens" for compounds that rapidly and durably promote neuroplasticity. Psilocybin is the first naturally occurring psychoplastogen to be studied clinically. The dendritic spine data suggest that integration therapy — the post-session psychotherapy that helps patients process and consolidate their insights — is most effective when conducted within the days-to-weeks window when neuroplastic changes are maximal, because the brain is literally more capable of structural reorganization during this period than at any other time.

The Mystical Experience: Not a Side Effect — the Active Ingredient

The most unusual finding in the psilocybin smoking literature is the dose-response relationship — unusual because the dose in question is not pharmacological. It is phenomenological. Participants who reported more intense mystical experiences during their psilocybin sessions had significantly higher smoking abstinence rates at 6-month follow-up. The correlation (r=0.57, p<0.05) held after controlling for expectancy, therapeutic alliance, preparation quality, and baseline motivation to quit.

The Mystical Experience Questionnaire (MEQ30) operationalizes mystical experience across seven dimensions: unity (sense of oneness with all things), noetic quality (sense of encountering ultimate reality), sacredness, deeply felt positive mood, transcendence of time and space, paradoxicality, and ineffability. High MEQ30 scores, rather than total drug dose, are what predicted quit success. This is extraordinary in pharmacology — where the rule is that dose predicts effect. Here, the subjective quality of the experience predicts effect, independent of dose.

What does a mystical experience actually do to addiction? The qualitative data from Johnson's follow-up interviews points to a consistent mechanism: participants describe a shift in the perceived importance of smoking relative to a suddenly more vivid sense of life's significance. They do not report suppressed cravings. They report that the craving continued but felt beside the point — as though it was addressed to a version of themselves they no longer recognized as current. One participant described it as "the smoking belonged to a self I saw from the outside, and I didn't go back in."

This is identity discontinuity as therapeutic mechanism. The mystical experience does not resolve the addiction. It creates a biographical rupture — a before and after — that allows the brain to encode a new self-model that excludes smoking, rather than fighting the existing self-model that includes it.

Share to Instagram

Save this image, post it to your Instagram story or feed, and tag @ootwchocolate. Link in bio.

Download Image Close